Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) (COVIMAR)

NCT04710199 PHASE2 COMPLETED

Maraviroc (MVC) is a drug, very well tolerated, it has been seen that MVC has properties of modulating the immune system, exerting an anti-inflammatory effect in different diseases. In COVID-19, very high levels of inflammation occur that cause organs and systems to be damaged. MVC could reduce this inflammation achieving a better prognosis of COVID-19.

Details

Lead sponsor	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Phase	PHASE2
Status	COMPLETED
Enrolment	44
Start date	Tue Feb 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jul 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Virus Diseases

Interventions

• Maraviroc experimental group
• Standard treatment

Countries

Spain